Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497310 | 0.86 | KDM4E (0.52) | MAPTHTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9881006 | 0.83 | MAPK1 (0.53) | MAPTHTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4658374 | 0.82 | ALDH1A1 (0.44) | MAPTSMN1; SMN2ALDH1A1KDM4ENPC1 | |
| SCHEMBL497345 | 0.80 | HTT (0.49) | MAPTHTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL497373 | 0.76 | ALDH1A1 (0.48) | MAPTHTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9881008 | 0.71 | ALDH1A1 (0.47) | MAPTSMN1; SMN2ALDH1A1KDM4ERXFP1 | |
| SCHEMBL7097532 | 0.70 | HTR1A (0.50) | MAPTHTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL497654 | 0.69 | MAPK1 (0.52) | MAPTALDH1A1KDM4EELANEMEN1 | |
| SCHEMBL9881003 | 0.69 | ALDH1A1 (0.44) | MAPTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL7694158 | 0.69 | KMT2A (0.55) | MAPTHTTALDH1A1KDM4EHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999112-B1 | SUBSTITUTED 2-AMINO-4-PHENYL-DIHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-8106204-B2 | Substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20090118329-A1 | Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | US | disclosed |
| CN-101395137-A | Substituted 2-amino-4-phenyl-dhydroquinolines, method for the production thereof, use thereof as medicaments, and medicaments containing them | SANOFI AVENTIS (FR) | 2009-03-25 | — | — | CN | disclosed |
| EP-1999112-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-D HYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | Sanofi-Aventis (FR) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107246-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI-AVENTIS (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118329-A1 | Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use | NHERF1, SLC10A1, SLC9A3 | MAPT 4685/4885HTT 1048/4885SMN1; SMN2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.